WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

In the PROTECT trial of patients with biopsy-proven IgAN, sparsentan met the primary endpoint with a significantly greater geometric mean percent reduction in urine protein-to-creatinine ratio (UPCR) vs active comparator irbesartan at the interim 36-week analysis (−49.8% vs −15.1%, respectively; P<.0001) (Heerspink et al. Lancet. 2023). Based on these data, sparsentan was granted accelerated approval in the US for adults with primary IgAN at risk of rapid disease progression. Here we present key efficacy results from the final analysis of the PROTECT double-blind period (≈2 years) on proteinuria and kidney function, including subgroup analyses of kidney function by baseline proteinuria.